CA2915279A1 - Compositions and methods of immunizing against c. difficile - Google Patents

Compositions and methods of immunizing against c. difficile Download PDF

Info

Publication number
CA2915279A1
CA2915279A1 CA2915279A CA2915279A CA2915279A1 CA 2915279 A1 CA2915279 A1 CA 2915279A1 CA 2915279 A CA2915279 A CA 2915279A CA 2915279 A CA2915279 A CA 2915279A CA 2915279 A1 CA2915279 A1 CA 2915279A1
Authority
CA
Canada
Prior art keywords
day
administration
days
toxin
difficile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2915279A
Other languages
English (en)
French (fr)
Inventor
Patricia PIETROBON
Ginamarie FOGLIA
Guy DE BRUYN
Sanjay Gurunathan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SANOFI PASTEUR Inc
Original Assignee
SANOFI PASTEUR Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51168412&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2915279(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by SANOFI PASTEUR Inc filed Critical SANOFI PASTEUR Inc
Publication of CA2915279A1 publication Critical patent/CA2915279A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2915279A 2013-06-14 2014-06-13 Compositions and methods of immunizing against c. difficile Abandoned CA2915279A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361835246P 2013-06-14 2013-06-14
US61/835,246 2013-06-14
PCT/US2014/042298 WO2014201346A1 (en) 2013-06-14 2014-06-13 Compositions and methods of immunizing against c. difficile

Publications (1)

Publication Number Publication Date
CA2915279A1 true CA2915279A1 (en) 2014-12-18

Family

ID=51168412

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2915279A Abandoned CA2915279A1 (en) 2013-06-14 2014-06-13 Compositions and methods of immunizing against c. difficile

Country Status (12)

Country Link
US (4) US9730994B2 (enExample)
EP (1) EP3007724B1 (enExample)
JP (1) JP6691477B2 (enExample)
KR (1) KR20160020543A (enExample)
CN (1) CN105611942A (enExample)
AU (1) AU2014277981B2 (enExample)
BR (1) BR112015031088A2 (enExample)
CA (1) CA2915279A1 (enExample)
MX (1) MX2015017257A (enExample)
SG (1) SG11201510166YA (enExample)
TW (1) TWI648063B (enExample)
WO (1) WO2014201346A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR086199A1 (es) 2011-04-22 2013-11-27 Wyeth Llc Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
SG11201510166YA (en) 2013-06-14 2016-01-28 Sanofi Pasteur Inc Compositions and methods of immunizing against c. difficile
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
MX2020003756A (es) * 2017-09-28 2020-07-29 Pfizer Composiciones y metodos para obtener una respuesta inmune contra clostridium difficile.
WO2021255690A2 (en) 2020-06-19 2021-12-23 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071759A (en) 1986-05-30 1991-12-10 The United States Of America As Represented By The Secretary Of The Army Hybridoma cell lines and monoclonal antibodies to clostridum difficile toxins A and B
US6969520B2 (en) 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
EP2305303A3 (en) 1997-10-20 2013-11-13 Sanofi Pasteur Biologics Co. Immunization against Clostridium difficile disease
AU2008299885C1 (en) * 2007-09-14 2015-06-25 Sanofi Pasteur Biologics, Llc Pharmaceutical compositions containing clostridium difficile toxoids A and B
GB0921288D0 (en) 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
AR086199A1 (es) 2011-04-22 2013-11-27 Wyeth Llc Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos
AR089797A1 (es) 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes
GB201206070D0 (en) 2012-04-04 2012-05-16 Health Prot Agency Clostridium difficile antigens
HK1213917A1 (zh) 2013-03-15 2016-07-15 Sanofi Pasteur, Inc. 類霉素、組合物及相關方法
KR20150133770A (ko) * 2013-03-15 2015-11-30 사노피 파스퇴르 인코포레이티드 톡소이드, 조성물 및 관련 방법
SG11201510166YA (en) 2013-06-14 2016-01-28 Sanofi Pasteur Inc Compositions and methods of immunizing against c. difficile

Also Published As

Publication number Publication date
TWI648063B (zh) 2019-01-21
US20170304423A1 (en) 2017-10-26
US20210145956A1 (en) 2021-05-20
WO2014201346A1 (en) 2014-12-18
EP3007724A1 (en) 2016-04-20
JP6691477B2 (ja) 2020-04-28
BR112015031088A2 (pt) 2017-07-25
US20200113991A1 (en) 2020-04-16
US11419930B2 (en) 2022-08-23
US9730994B2 (en) 2017-08-15
KR20160020543A (ko) 2016-02-23
US20160120968A1 (en) 2016-05-05
TW201536314A (zh) 2015-10-01
JP2016521754A (ja) 2016-07-25
MX2015017257A (es) 2016-11-11
CN105611942A (zh) 2016-05-25
SG11201510166YA (en) 2016-01-28
AU2014277981A1 (en) 2016-01-07
AU2014277981B2 (en) 2019-06-20
EP3007724B1 (en) 2023-07-05

Similar Documents

Publication Publication Date Title
US11419930B2 (en) Compositions and methods for immunizing against C. difficile
Enioutina et al. The induction of systemic and mucosal immune responses to antigen-adjuvant compositions administered into the skin: alterations in the migratory properties of dendritic cells appears to be important for stimulating mucosal immunity
TWI513464B (zh) 新穎之佐劑組成物
Carcelén et al. The chimerical multi-component Q protein from Leishmania in the absence of adjuvant protects dogs against an experimental Leishmania infantum infection
RU2559782C2 (ru) Набор для детекции спор, происходящих из микобактерий
US20240189410A1 (en) Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile
Saravanan et al. Protective immune response to liposome adjuvanted high potency foot-and-mouth disease vaccine in Indian cattle
Jarosova et al. Effects of oil-based adjuvants on the immune response of pigs after dermal administration of antigen and evaluation of the immunization level after a subsequent Actinobacillus pleuropneumoniae challenge in pigs
JP7399865B2 (ja) 哺乳動物における趾皮膚炎に使用されるワクチン組成物
US20210220459A1 (en) Vaccine compositions
MacDonald et al. Efficacy of a single dose hepatitis B depot vaccine
CA3082608C (en) Vaccine compositions for use against digital dermatitis in a mammal
TW202612726A (zh) 誘發針對困難梭狀芽孢桿菌的免疫反應之免疫原性組成物和方法
AU776364B2 (en) Veterinary vaccines
Mohammad Pour-dounighi et al. Humoral immune response to Diphtheria and Tetanus toxoids by intranasal administration
Pour-Dounighi et al. Humoral immune response to Diphtheria and Tetanus toxoids by intranasal administration.

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190613

FZDE Discontinued

Effective date: 20210831